Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer's disease

Stephanie R. Murphy, Catherine C.Y. Chang, Godwin Dogbevia, Elena Y. Bryleva, Zachary Bowen, Mazahir T. Hasan, Ta Yuan Chang*

*Corresponding author for this work
34 Citations (Scopus)


Both genetic inactivation and pharmacological inhibition of the cholesteryl ester synthetic enzyme acyl-CoA:cholesterol acyltransferase 1 (ACAT1) have shown benefit in mouse models of Alzheimer's disease (AD). In this study, we aimed to test the potential therapeutic applications of adeno-associated virus (AAV)-mediated Acat1 gene knockdown in AD mice. We constructed recombinant AAVs expressing artificial microRNA (miRNA) sequences, which targeted Acat1 for knockdown. We demonstrated that our AAVs could infect cultured mouse neurons and glia and effectively knockdown ACAT activity in vitro. We next delivered the AAVs to mouse brains neurosurgically, and demonstrated that Acat1-targeting AAVs could express viral proteins and effectively diminish ACAT activity in vivo, without inducing appreciable inflammation. We delivered the AAVs to the brains of 10-month-old AD mice and analyzed the effects on the AD phenotype at 12 months of age. Acat1-targeting AAV delivered to the brains of AD mice decreased the levels of brain amyloid-β and full-length human amyloid precursor protein (hAPP), to levels similar to complete genetic ablation of Acat1. This study provides support for the potential therapeutic use of Acat1 knockdown gene therapy in AD.

Original languageEnglish
JournalMolecular Therapy
Issue number8
Pages (from-to)1497-1506
Number of pages10
Publication statusPublished - 01.01.2013

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this